Overall survival · hormone‐sensitive prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · hormone‐sensitive prostate cancer
Degarelix showed no clear difference in serious adverse events compared with standard androgen suppression therapy (low certainty).
1 finding from 1 review
Quality of life · hormone‐sensitive prostate cancer
1 finding from 1 review
Cancer‐specific survival (24 months) (Number of cancer‐related deaths) · hormone‐sensitive prostate cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular events · hormone‐sensitive prostate cancer
It is very uncertain whether degarelix changes cardiovascular events compared with standard androgen suppression therapy (very low certainty).
1 finding from 1 review
Injection site pain · hormone‐sensitive prostate cancer
Degarelix probably leads to higher injection site pain compared with standard androgen suppression therapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib leads to lower progression‐free survival (absolute effect size estimates based on… compared with placebo (targeted agent versus placebo) (high certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with placebo (targeted agent versus placebo) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).
1 finding from 1 review
Health‐related quality of life · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
Stone clearance · adult patients presenting with symptoms of ureteral stone disease
Alpha‐blockers may leads to higher stone clearance compared with standard therapy (low certainty).
1 finding from 1 review
Stone expulsion time · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review
Pain episodes · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review
Dose of diclofenac (mg) · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review
Hospital admissions · adult patients presenting with symptoms of ureteral stone disease
Alpha‐blockers showed no clear difference in hospitalisation compared with placebo (moderate certainty).
1 finding from 1 review
Surgical intervention · adult patients presenting with symptoms of ureteral stone disease
Alpha‐blockers showed no clear difference in surgical intervention compared with placebo (high certainty).
1 finding from 1 review
Major adverse events · adult patients presenting with symptoms of ureteral stone disease
Alpha‐blockers showed no clear difference in major adverse events compared with standard therapy (low certainty).
1 finding from 1 review
Stone expulsion time · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review
Pain episodes · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review
Dose of diclofenac · adult patients presenting with symptoms of ureteral stone disease
1 finding from 1 review